Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03856034

Laparotomy Versus Percutaneous Endoscopic Correction of Myelomeningocele

The purpose of this study is to evaluate the feasibility of a fetoscopic surgical technique for antenatal correction of fetal myelomeningocele. Two surgical approaches will be utilized. The percutaneous approach will be offered to participants with a posterior placenta. The laparotomy/uterine exteriorization approach will be offered to participants regardless of placental location.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

University of Southern California / Huntington Memorial Hospital, Los Angeles, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Myelomeningocele (including myeloschisis) at level T1 through S1 with hindbrain herniation. Lesion level and hindbrain herniation will be confirmed by MRI and ultrasonography.
  • Maternal age ≥18 years.
  • Gestational age of 19 to 27 6/7 weeks' gestation as determined by clinical information and evaluation of first ultrasound.
  • Balanced karyotype with written confirmation of culture results. Results by fluorescence in situ hybridization (FISH) will be acceptable if the patient is at 24 weeks or more.
  • Positive evaluation of social work consult indicating the patient is capable of consenting to the procedure and has the appropriate social support system to participate in the study.
  • Positive evaluation from pediatric neurology consult.
  • Willing to remain in the greater Wellington or Pasadena area (within a 30-minute car ride) for remainder of the pregnancy and deliver at Wellington Regional Medical Center or Huntington Memorial Hospital for postnatal management. The participants must be willing to return to our center for the 12, 24, 30, 48, and 60 months for follow-up evaluation.

Exclusion criteria

  • Multiple gestation
  • Insulin-dependent pregestational diabetes
  • Presence of a fetal anomaly not related to myelomeningocele. A fetal echocardiogram will be conducted before surgery and if the finding is abnormal, the patient will be excluded.
  • Fetal kyphosis of 30 degrees or more, assessed by ultrasound or MRI.
  • Presence of uterine cervical cerclage or history of incompetent cervix.
  • Placenta previa or placental abruption.
  • Short cervix < 25 mm measured by cervical ultrasound.
  • Obesity as defined by body mass index (BMI) of 35 or greater.
  • History of previous spontaneous singleton delivery prior to 37 weeks.
  • Maternal-fetal Rh isoimmunization, Kell sensitization or a history of neonatal alloimmune thrombocytopenia.
  • Maternal HIV or Hepatitis-B status positive because of the increased risk of transmission to the fetus during maternal-fetal surgery. If the patient's HIV or Hepatitis B status is unknown, the patient must be tested and found to have negative results before she can be enrolled.
  • Known Hepatitis-C positivity. If the patient's Hepatitis C status is unknown, she does not need to be screened.
  • Uterine anomaly such as large (greater than 6 cm) fibroids, cervical fibroids or multiple fibroids or Mullerian duct abnormality.
  • Other maternal medical condition which is a contraindication to surgery or anesthesia.
  • Patient does not have a support person (e.g., husband, partner, parents).
  • Inability to comply with the travel and follow-up requirements of the study.
  • Patient does not meet psychosocial criteria as determined by the social worker evaluation.
  • Participation in another intervention study that influences maternal and fetal morbidity and mortality.
  • Maternal hypertension as determined by the investigator, which would increase the risk of preeclampsia or preterm delivery (including, but not limited to: uncontrolled hypertension, chronic hypertension with end organ damage and new onset hypertension in current pregnancy).
  • Bicornuate uterus or any other uterine malformation the PI decides is not safe for surgery.
  • Nickel allergy.
  • Maternal request to undergo open fetal surgery for the antenatal correction of open spina bifida at our institution primarily or after failed fetoscopic approach.
  • Known maternal hypersensitivity to bovine collagen or chondroitin materials.

Treatment and study plan

fetoscopy

Device

Patients will receive fetoscopic repair of myelomeningocele. Patients with an anterior placenta will undergo the laparotomy with uterine exteriorization approach. Patients with a posterior placenta will undergo the percutaneous approach (or, if patient prefers, the laparotomy with uterine exteriorization approach).

Primary outcomes

  1. Rate of successful in-utero fetoscopic myelomeningocele closures using either laparotomy or percutaneous techniques

    Time frame: At time of surgery until delivery, up to 21 weeks

    Successful fetoscopic closure of the spinal defect and reversal of hindbrain herniation as assessed by ultrasound and MRI prior to delivery

Study contacts

Contact information is provided by the study sponsor or research team.

Ramen Chmait, MD

CONTACT

[email protected]

626-356-3360

Ruben Quintero, MD

CONTACT

[email protected]

720-753-3825

Sponsors and collaborators

Lead sponsor

USFetus

Other

Collaborators

  • University of Southern California
  • Wellington Hospital

Registry information

Official study title

In Utero Endoscopic Correction of Myelomeningocele: Laparotomy Versus Percutaneous - A Pilot Study

Important dates

Study start
2018
Primary completion
2020
Study completion
2027
First posted
Feb 27, 2019
Registry last updated
Nov 13, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.